NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jan 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
6/8 — Strong
RYTARY (carbidopa and levodopa) by Viatris (2) is dopa decarboxylase inhibitors [moa]. Approved for parkinson disease. First approved in 2015.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYTARY is an extended-release oral capsule combining carbidopa and levodopa, approved in January 2015 for treating Parkinson's disease, post-encephalitic parkinsonism, parkinsonism, and manganese intoxication in adults. It works as a DOPA decarboxylase inhibitor, a foundational mechanism in Parkinson's treatment that has been standard-of-care for decades. The extended-release formulation aims to provide more consistent dopamine replacement and reduce dosing frequency compared to immediate-release carbidopa/levodopa combinations. RYTARY is positioned as a core symptomatic therapy in the Parkinson's disease treatment algorithm, typically used as first-line or early adjunctive therapy.
$0.3BPart D
2.6 years to LOEMechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid
Indications (1)
Clinical Trials (1)
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
52 enrolled
Parkinson Disease
Why This Matters for Your Career
Worked on RYTARY at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.